PRESS RELEASE: New Study Highlights Role of Stromal Support in Bioengineered Human Intestinal Models
13 November 2024
New study by Prof Stefan Przyborski at Durham University enhances drug testing models with stromal support in bioengineered human intestinal tissue.
PRESS RELEASE: REPROCELL’s New Clinical Pipeline: Tumor Infiltrating Lymphocyte Infusion Therapy (TIL Therapy)
08 February 2024
REPROCELL will soon add a third clinical pipeline, TIL therapy for cervical cancer, in addition to Stemchymal for spinocerebellar ataxia, and iPSC-derived neuroglial cells for ALS.
Histocell obtains AEMPS authorisation and GMP certification for its new manufacturing plant for cell therapy and associated biological medicinal products in Larrabetzu
31 January 2024
REPROCELL's clinical stem cells manufacturing partner Histocell has obtained AEMPS authorisation and GMP certification for its new manufacturing plant.
Cellcolabs announces partnership with REPROCELL: Global distributorship for research- and GMP-grade MSC and MSC derivatives
15 January 2024
SOLNA, Sweden and YOKOHAMA, Japan – Cellcolabs AB, a spin-out of the Karolinska Institute specialized in manufacturing both research- and GMP-grade mesenchymal stem cells (MSC), and REPROCELL Inc., Japan’s first induced pluripotent stem cell (iPSC) company, have partnered to globally distribute the high-quality MSCs and MSC derivatives manufactured by Cellcolabs for research and clinical applications. This agreement also includes exclusive distribution in Japan.
End of 2023 Newsletter
15 December 2023
Discover the latest advancements in stem cell and drug discovery research at REPROCELL. From GMP MSC production to Pharmacology-AI services, explore how REPROCELL is revolutionizing the field. Stay updated with their collaborations and partnerships for precision medicine and clinical capabilities.
REPROCELL Announces License Agreement with Gameto for the Advancement of its Program to Improve Assisted Fertility using iPSCs
04 October 2023
Gameto plans to use the iPSC line to advance its program, Fertilo, designed to improve IVF and egg freezing.
Joint Research Agreement with Keio University on Tumor-Infiltrating Lymphocyte Therapy for Cervical Cancer
28 June 2023
REPROCELL has entered into a joint research agreement with Keio University regarding the transfer of technology to produce Tumor Infiltrating Lymphocytes (TIL).
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
25 May 2023
[PRESS RELEASE] Announcement of Results of Phase II Clinical Trial in Japan for Stemchymal®, a Regenerative Medicine Product for Spinocerebellar Ataxia
REPROCELL offers mesenchymal stem cell based CDMO services to manufacture Advanced Therapies Medicinal Products
23 May 2023
REPROCELL will now offer CDMO services to manufacture ATMPs generated from mesenchymal stem cells (MSC) through a partnership with Histocell.
Lantern Pharma Selects REPROCELL USA to Provide Support for the Phase 2 Harmonic™ Clinical Trial
03 May 2023
REPROCELL USA has been awarded a contract to provide support for Lantern Pharma’s Phase 2 clinical trial entitled “HARMONIC”.
REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPS Service to domestic and overseas customers
13 October 2022
REPROCELL Inc. and JTB Corp. will begin marketing Personal iPS (REPROCELL's iPSC storage and production service) overseas through the JMHC.
REPROCELL Inc. and CIRM sign MOU for special access to clinical iPSCs
05 October 2022
Learn why REPROCELL Inc. has agreed to join the California Institute for Regenerative Medicine’s (CIRM) Industry Resource Partner Program.
REPROCELL and BioBridge Global sign Memorandum of Understanding to accelerate global manufacturing services using clinical iPSCs
04 October 2022
REPROCELL and Texas-based BioBridge Global have signed a Memorandum of Understanding to enhance their strategic collaborative relationship. Find out more.
Bioserve India granted NABL accreditation in the field of Genomics Testing
09 August 2022
Bioserve Biotechnologies India Pvt Ltd has received NABL accreditation for Medical Testing in the field of Genomics Testing Services.
Completion of Clinical Phase II Trials of Stemchymal in Japan
16 May 2022
We will endeavor to obtain clinical approval as soon as possible so that we can provide the new treatment to patients suffering from this disease.
REPROCELL signs Strategic Collaboration Agreement with TEXCELL to boost its GMP iPSC - Master Cell Bank Manufacturing Service
02 September 2021
REPROCELL USA has launched a new service to manufacture GMP iPSC-Master Cell Banks (MCB), compliant with the regulatory standards and guidelines.
REPROCELL signs MSA with TEXCELL for Master Cell Bank Manufacturing
18 August 2021
Read about REPROCELL's Master Service Agreement with TEXCELL JAPAN a TEXCELL Group Company for GMP iPSC - Master Cell Banks (MCB) Manufacturing.
REPROCELL's solution for GMP iPSC development - Seed iPSC Manufacturing Suite
29 June 2021
Read more about REPROCELL's new Seed iPSC Manufacture Suite to provide supply for the increasing demand of iPSC-derived Master Cell Banks
REPROCELL Launch New Testing Service for Identification of the Indian (Delta) Covid-19 variant
21 June 2021
Reprocell will launch in Japan a new testing service of identification for Covid-19 variants including India (Delta), UK, South Africa, and Brazil variants
Completion of administration of Stemchymal to all enrolled patients in phase II clinical trial in Japan
24 May 2021
The administrations of Stemchymal have been completed to all enrolled patients in phase II clinical trial for the treatment of SCA in Japan.